Fighting time: the critical importance of pre-TAVR mortality risk prediction.

IF 3.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Jasmin Shamekhi, Marius Ebert, Angelina Lorek, Irina Eckardt, Baravan Al-Kassou, Mustafa Mousa Basha, Marcel Weber, Miriam Silaschi, Farhad Bakhtiary, Georg Nickenig, Sebastian Zimmer
{"title":"Fighting time: the critical importance of pre-TAVR mortality risk prediction.","authors":"Jasmin Shamekhi, Marius Ebert, Angelina Lorek, Irina Eckardt, Baravan Al-Kassou, Mustafa Mousa Basha, Marcel Weber, Miriam Silaschi, Farhad Bakhtiary, Georg Nickenig, Sebastian Zimmer","doi":"10.1007/s00392-025-02698-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Symptomatic severe aortic valve stenosis (AS) is a life-threatening condition requiring prompt medical attention. While transcatheter aortic valve replacement (TAVR) is an effective treatment, current scheduling practices often do not account for individual patient risk profiles due to limited data on mortality rates during the waiting period and a lack of viable risk assessment. Consequently, non-prioritized wait times may be unacceptably long for high-risk patient populations.</p><p><strong>Objective: </strong>This study aimed to evaluate the mortality rate of patients with symptomatic severe AS awaiting TAVR and identify pragmatic clinical risk predictors during this period.</p><p><strong>Methods: </strong>Between January 2019 and December 2023, 2,454 patients with symptomatic severe AS, were scheduled for TAVR after an interdisciplinary Heart Team discussion at the Heart Center Bonn. Mortality during the waiting period was assessed, and the characteristics of survivors (patients who underwent TAVR) were compared to non-survivors (patients who died before the procedure).</p><p><strong>Results: </strong>The median waiting time for TAVR was 41 days. A total of 105 (4.3%) patients died during the waiting period, with a median time to death of 29 days. By comparison, 30 day post-TAVR mortality, including the intervention, was 1.7%. Multivariate regression analysis identified independent predictors of pre-TAVR mortality including reduced left ventricular ejection fraction, decreased estimated glomerular filtration rate, mitral regurgitation, tricuspid regurgitation, and advanced heart failure symptoms. An IMPACT score, incorporating these parameters, strongly predicted outcome with a hazard ratio for mortality of 2.1 greatly outperforming both EuroSCORE II and STS-PROM. The IMPACT score of ≥ 5 identified high-risk patients with a pre-TAVR mortality rate of 12.6%.</p><p><strong>Conclusion: </strong>The mortality rate for patients with symptomatic severe AS awaiting TAVR is unacceptably high. Utilizing the IMPACT score could enable precise risk stratification, identifying patients who require urgent or prioritized intervention to improve outcomes.</p>","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00392-025-02698-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Symptomatic severe aortic valve stenosis (AS) is a life-threatening condition requiring prompt medical attention. While transcatheter aortic valve replacement (TAVR) is an effective treatment, current scheduling practices often do not account for individual patient risk profiles due to limited data on mortality rates during the waiting period and a lack of viable risk assessment. Consequently, non-prioritized wait times may be unacceptably long for high-risk patient populations.

Objective: This study aimed to evaluate the mortality rate of patients with symptomatic severe AS awaiting TAVR and identify pragmatic clinical risk predictors during this period.

Methods: Between January 2019 and December 2023, 2,454 patients with symptomatic severe AS, were scheduled for TAVR after an interdisciplinary Heart Team discussion at the Heart Center Bonn. Mortality during the waiting period was assessed, and the characteristics of survivors (patients who underwent TAVR) were compared to non-survivors (patients who died before the procedure).

Results: The median waiting time for TAVR was 41 days. A total of 105 (4.3%) patients died during the waiting period, with a median time to death of 29 days. By comparison, 30 day post-TAVR mortality, including the intervention, was 1.7%. Multivariate regression analysis identified independent predictors of pre-TAVR mortality including reduced left ventricular ejection fraction, decreased estimated glomerular filtration rate, mitral regurgitation, tricuspid regurgitation, and advanced heart failure symptoms. An IMPACT score, incorporating these parameters, strongly predicted outcome with a hazard ratio for mortality of 2.1 greatly outperforming both EuroSCORE II and STS-PROM. The IMPACT score of ≥ 5 identified high-risk patients with a pre-TAVR mortality rate of 12.6%.

Conclusion: The mortality rate for patients with symptomatic severe AS awaiting TAVR is unacceptably high. Utilizing the IMPACT score could enable precise risk stratification, identifying patients who require urgent or prioritized intervention to improve outcomes.

战斗时间:tavr前死亡风险预测的关键重要性。
背景:症状性严重主动脉瓣狭窄(AS)是一种危及生命的疾病,需要及时就医。虽然经导管主动脉瓣置换术(TAVR)是一种有效的治疗方法,但由于等待期死亡率数据有限以及缺乏可行的风险评估,目前的调度实践往往不能考虑到个体患者的风险概况。因此,对于高危患者群体来说,非优先级的等待时间可能长得令人无法接受。目的:本研究旨在评估有症状的严重AS患者等待TAVR的死亡率,并确定此期间实用的临床风险预测因素。方法:2019年1月至2023年12月,波恩心脏中心跨学科心脏小组讨论后,2454名有症状的严重AS患者计划接受TAVR治疗。评估等待期间的死亡率,并将幸存者(接受TAVR的患者)与非幸存者(手术前死亡的患者)的特征进行比较。结果:TAVR的中位等待时间为41天。共有105例(4.3%)患者在等待期死亡,中位死亡时间为29天。相比之下,包括干预在内的tavr术后30天死亡率为1.7%。多因素回归分析确定了tavr前死亡率的独立预测因素,包括左室射血分数降低、肾小球滤过率降低、二尖瓣反流、三尖瓣反流和晚期心力衰竭症状。纳入这些参数的IMPACT评分强有力地预测了结果,死亡率风险比为2.1,大大优于EuroSCORE II和STS-PROM。IMPACT评分≥5确定高危患者tavr前死亡率为12.6%。结论:有症状的严重AS患者等待TAVR的死亡率高得令人无法接受。利用IMPACT评分可以实现精确的风险分层,确定需要紧急或优先干预以改善预后的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Research in Cardiology
Clinical Research in Cardiology 医学-心血管系统
CiteScore
11.40
自引率
4.00%
发文量
140
审稿时长
4-8 weeks
期刊介绍: Clinical Research in Cardiology is an international journal for clinical cardiovascular research. It provides a forum for original and review articles as well as critical perspective articles. Articles are only accepted if they meet stringent scientific standards and have undergone peer review. The journal regularly receives articles from the field of clinical cardiology, angiology, as well as heart and vascular surgery. As the official journal of the German Cardiac Society, it gives a current and competent survey on the diagnosis and therapy of heart and vascular diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信